Australia markets closed

Taro Pharmaceutical Industries Ltd. (TARO)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
52.92-0.32 (-0.60%)
At close: 04:00PM EST
53.47 -0.45 (-0.84%)
After hours: 04:01PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 2.00B
Enterprise value 979.05M
Trailing P/E 280.21
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.56
Price/book (mrq)1.20
Enterprise value/revenue 1.72
Enterprise value/EBITDA -2.66

Trading information

Stock price history

Beta (5Y monthly) 0.93
52-week change 3-24.90%
S&P500 52-week change 324.55%
52-week high 380.00
52-week low 351.10
50-day moving average 359.79
200-day moving average 369.38

Share statistics

Avg vol (3-month) 313.81k
Avg vol (10-day) 318.88k
Shares outstanding 537.58M
Implied shares outstanding 637.58M
Float 88.09M
% held by insiders 178.48%
% held by institutions 112.99%
Shares short (14 Nov 2021) 498.06k
Short ratio (14 Nov 2021) 47.49
Short % of float (14 Nov 2021) 41.21%
Short % of shares outstanding (14 Nov 2021) 40.26%
Shares short (prior month 14 Oct 2021) 4115.76k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 327 Dec 2018
Ex-dividend date 409 Dec 2018
Last split factor 22:1
Last split date 326 July 2001

Financial highlights

Fiscal year

Fiscal year ends 30 Mar 2021
Most-recent quarter (mrq)29 Sept 2021

Profitability

Profit margin 1.35%
Operating margin (ttm)24.85%

Management effectiveness

Return on assets (ttm)3.78%
Return on equity (ttm)0.51%

Income statement

Revenue (ttm)567.59M
Revenue per share (ttm)14.97
Quarterly revenue growth (yoy)-7.60%
Gross profit (ttm)296.66M
EBITDA 166.17M
Net income avi to common (ttm)7.68M
Diluted EPS (ttm)0.20
Quarterly earnings growth (yoy)-48.30%

Balance sheet

Total cash (mrq)972.56M
Total cash per share (mrq)25.87
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)2.30
Book value per share (mrq)44.50

Cash flow statement

Operating cash flow (ttm)85.89M
Levered free cash flow (ttm)129.45M